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Abstract The objective of this study was to determine the
prevalence and risk factors of low bone mineral density
(BMD) in patients with spondylarthropathies (SpA) at an
early stage of disease. In this cross-sectional study, the
BMD of lumbar spine and hips was measured in 130
consecutive early SpA patients. The outcome measure
BMD was defined as (1) osteoporosis, (2) osteopenia, and
(3) normal bone density. Logistic regression analyses were
used to investigate relations between the following varia-
bles: age, gender, disease duration, diagnosis, HLA-B27,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI), Bath Ankylosing Spondylitis Functional
Index (BASFI), Bath Ankylosing Spondylitis Metrology
Index (BASMI), extra-spinal manifestations and medica-
tion, with outcome measure low BMD (osteopenia and/or
osteoporosis). The SpA population had a median time since
diagnosis of 6.6 months and a disease duration of 6.3 years.
In total, 9% of the early SpA patients had osteoporosis,
38% osteopenia, and 53% normal BMD. On univariate
analyses, male gender, diagnosis of ankylosing spondylitis,
increased CRP, high BASFI, and high BASMI were
significantly associated with low BMD. Factors showing
a relation with low BMD in the multivariate model were
male gender (OR 4.18, 95% confidence interval (CI)
1.73–10.09), high BASMI (OR 1.54, 95% CI 1.14–2.07),
and high BASFI (OR 1.18, 95% CI 1.00–1.39). In early
SpA patients, a high frequency (47%) of low BMD in
femur as well as in lumbar spine was found. Low BMD
was associated with male gender and decreased functional
capacity. These findings emphasize the need for more
alertness for osteoporosis and osteopenia in spondylarthr-
opathy patients at an early stage of the disease.
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Introduction
Spondylarthropathies (SpA) comprise a group of interrelated
chronic inflammatory diseases, i.e. ankylosing spondylitis
(AS), psoriatic arthritis, SpA associated with inflammatory
bowel diseases (IBD), reactive arthritis, juvenile onset SpA,
and undifferentiated SpA. These diseases share several
clinical features such as inflammation of the axial joints,
asymmetric oligoarthritis (especially of the lower extremities),
and enthesitis.
Loss of bone mass (osteopenia or osteoporosis) in spine
and femur is a well-recognized and important complication
of long-standing AS [1, 2] because a reduced bone mass
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will increase the risk of vertebral fractures [1, 3–5]. In
addition, vertebral deformities will contribute to hyper-
kyphosis and functional loss [4, 6], which, in rare cases,
may even cause neurological deficits due to spinal cord
injuries [7–9].
In long-standing AS, reduced bone mass is reflected by
low bone mineral density (BMD), particularly in the hips.
Lumbar BMD values will often be normal or even high as
the presence of bridging syndesmophytes may mask
osteoporosis in AS patients at an advanced stage of the
disease [1, 2, 10, 11].
Bone loss is a well-known complication of AS with a
long disease duration; however, little is known about the
degree of osteoporosis in the total group of SpA patients.
Until now, no studies are available quantifying the
magnitude of osteoporosis in a population of early SpA
patients. Therefore, the aim of this study was to investigate
the prevalence of osteopenia and osteoporosis and their
demographic and disease-related risk factors in SpA
patients at an early stage of the disease.
Materials and methods
Study population
Patients with a recent diagnosis of SpA (according to the
ESSG criteria) [12] as well as inflammatory back pain [13]
were consecutively enrolled in a prospective early spondy-
larthropathy cohort at the Jan van Breemen Institute, a
major outpatient rheumatology clinic in Amsterdam. The
diagnosis of spondylarthropathy consisted of AS, undifferen-
tiated SpA, patients with inflammatory back pain, and
psoriatic arthritis (axial disease: all psoriatic arthritis patients
fulfilled the radiographic modified New York criteria) [14],
inflammatory bowel diseases, or reactive arthritis. Patients
with mechanical back pain were excluded from the study.
For the present study, we used clinical characteristics
and bone mineral density measurements made with dual
X-ray absorptiometry (DXA) scans from all patients at
inclusion.
At inclusion, a verified medical history, physical exam-
ination, laboratory assessment, radiographs of the spine,
and a DXA scan were obtained from all SpA patients.
The following patient characteristics were collected: demo-
graphics (i.e., gender and age), disease-related variables,
such as time since diagnosis, disease duration (time since
first complaints), and presence of peripheral arthritis,
inflammatory bowel diseases, psoriasis, and uveitis. In
addition, disease activity score Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) [15] and functional
capacity scores Bath Ankylosing Spondylitis Functional
Index (BASFI) [16] and Bath Ankylosing Spondylitis
Metrology Index (BASMI) [17] were collected. Laboratory
assessment included erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), and HLA-B27 antigen. Other
possible BMD-related variables were obtained, such as data
on previous peripheral or vertebral fractures, menopausal
status, drug treatment, i.e., use of anti-osteoporotic, disease-
modifying anti-rheumatic drugs (DMARDs), non-steroidal
anti-inflammatory drugs (NSAIDs), corticosteroids, and
tumor necrosis factor alpha blocking agents (biologicals).
The study protocol was approved by the local Medical
Ethics Committee, and all participants gave their permission
by signing a form of informed consent.
Outcome measure
The outcome measure BMD was obtained from the lumbar
spine (L2–L4) and the left proximal femur using DXA
equipment (Lunar DPX-IQ, Madison, Wisconsin, USA),
which was certified for the study. The results were given
as BMD (g/cm2), T scores and Z scores. The T score
corresponds to the number of standard deviations (SD)
rom any result of the peak bone mass, and the Z score is the T
score with a correction for age and weight. T and Z score
estimations were computed from a large pooled US/Northern
Europe (UK/Scandinavia) reference population and were
adjusted for gender (as supplied by the manufacturer).
Osteopenia and osteoporosis were defined according to the
World Health Organization: (1) osteoporosis (T score≤−2.5
in the spine and/or hip), (2) osteopenia (−2.5<T score<−1.0
in the spine and/or hip, without osteoporosis), and (3)
normal bone density (T score≥−1.0 both in spine and hip)
[18].
Statistical analysis
Data are expressed as mean (standard deviation) or median
(interquartile ranges) as appropriate. For logistic regression,
the BMD data were dichotomized as normal bone density
(indicated by 0) and low bone density (osteoporosis and/or
osteopenia, indicated by 1). Differences in baseline charac-
teristics between SpA patients with osteopenia and/or
osteoporosis (low BMD) and SpA patients with normal
BMD were evaluated using independent t tests for normally
distributed variables, Mann–Whitney U tests for skewed
variables, and Pearson Chi-square tests for dichotomous
variables. Univariate logistic regression analyses were
performed to investigate associations between the presence
of low BMD and disease-related factors (p<0.05 was
considered statistically significant). Multivariate logistic
regression analyses were done by backward selection,
removing variables that showed an association with the
outcome measure with a p value above 0.10. All analyses
were done using SPSS 14.0 software.
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Results
Characteristics of the early SpA cohort
The baseline characteristics of 130 SpA patients included in
the study show a mean age of 38.0 (9.1), the majority being
male (66%), having a short time since diagnosis (6.6 months)
and a short disease duration (6.3 years) (Table 1). The SpA
group consisted of 72% AS patients, 12% undifferentiated
spondylarthropathies, 8% (axial) psoriatic arthritis, 4%
spondylarthropathies with inflammatory bowel diseases, and
4% reactive arthritis.
Only two women were postmenopausal, one of them
with a low and the other with a normal BMD. None of the
patients had a history of symptomatic vertebral fractures or
of osteoporotic peripheral fractures. Furthermore, none of
them had a drug history of corticosteroids or bisphospho-
nates, and most patients (95%) were being treated with
NSAIDs.
BMD measurements
All patients had a BMD measurement at a median period of
6.6 months (2.3–14.9 months) after diagnosis. Osteopenia
was present in 38% of the patients and osteoporosis in 9%,
whereas half of the early SpA population had a normal
BMD (Table 2). In this early SpA patient group, no
significant differences in the distribution of normal BMD,
osteopenia, and osteoporosis were found between hip and
lumbar spine.
Relation between BMD and disease-related variables
in early SpA patients
Differences between characteristics of SpA patients with
low BMD (osteopenia and/or osteoporosis) and normal
BMD are summarized in Table 3. Univariate analyses in
this table demonstrate that SpA patients with low BMD
were significantly more often male, had more often the
diagnosis AS, showed higher CRP levels, and had higher
BASFI and BASMI scores than patients with normal BMD.
No significant differences were found regarding age, time
since diagnosis, disease duration, HLA-B27, ESR, BASDAI,
extra-spinal manifestations, BMI, previous non-vertebral
Table 1 Baseline characteristics of early SpA patients
N=130
Demographic variables
Mena 86 (66)
Ageb (years) 38.0 (9.1)
Types of spondylarthropathies
Ankylosing spondylitisa 94 (72)
Undifferentiated spondylarthropathya 15 (12)
Psoriatic arthritisa 11 (8)
SpA and inflammatory bowel diseasea 5 (4)
Reactive arthritisa 5 (4)
Disease-related variables
Time since diagnosisc (months) 6.6 (2.3–14.9)
Disease durationc (years) 6.3 (3.2–11.3)
HLA-B27a, positive 96 (74)
ESRc (mm/h) 9.0 (4.3–18.8)
CRPc (mg/l) 5.0 (2.0–12.0)
BASFIc (0–10) 2.4 (0.9–4.5)
BASDAIb (0–10) 4.2 (2.3)
BASMIc (0–10) 1.0 (0.0–2.3)
Uveitisa 31 (24)
Psoriasisa 11 (9)
Inflammatory bowel diseasea 5 (4)
Peripheral arthritisa 43 (33)
NSAIDsa 123 (95)
DMARDsa 6 (5)
Biologicalsa 2 (2)
Other BMD-related variables
BMIb (kg/m2) 25.0 (3.8)
Postmenopausal statusa (N=44) 2 (2)
Previous non-vertebral fracturesa 53 (41)
Table 1 (continued)
N=130
BMD variables
BMD femurb 0.940 (0.170)
T score femurb −0.37 (1.06)
Z score femurb −0.32 (1.00)
BMD lumbar spineb 1.102 (0.216)
T score lumbar spineb −0.42 (1.51)
Z score lumbar spineb −0.46 (1.51)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASDAI
Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath
Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing
Spondylitis Metrology Index, NSAIDs non-steroidal anti-inflammatory
drugs, DMARDs disease-modifying anti-rheumatic drugs, BMI body
mass index
a Number (%)
bMean (SD)
cMedian (IQR)
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fractures, and postmenopausal status. The use of NSAIDs,
DMARDs, and biologicals showed no differences between
the two groups with low and normal BMD. Nearly all
patients in each group (93% vs. 96%) were treated with
NSAIDs. Only three patients in both groups used DMARDs,
and only two patients in the low BMD group were treated with
biologicals.
On univariate logistic regression analysis (Table 4), male
gender, AS diagnosis, increased CRP, high BASFI, and high
BASMI were significantly associated with low BMD (i.e.,
osteopenia and/or osteoporosis).
On multivariate logistic regression analysis (Table 4),
male gender, high BASMI, and high BASFI remained
associated with low BMD. These three variables had an
explained variation of 30.5% in the multivariate model.
The relation between gender and BMD levels clearly
shows (univariate and multivariate) that male patients with
SpA are more prone to develop low BMD at an early stage
of the disease than female patients. In 86 men, only 41%
had normal BMD, 47% had osteopenia, and 12% already
had osteoporosis. Among 44 (mostly premenopausal)
Table 2 Prevalence of normal BMD, osteopenia, and osteoporosis in
early SpA patients
Femur Lumbar spine Femur and lumbar spine
Normal BMD 90 (69.2%) 80 (61.5%) 70 (53.8%)
Osteopenia 37 (28.5%) 40 (30.8%) 49 (37.7%)
Osteoporosis 3 (2.3%) 10 (7.7%) 11 (8.5%)
Normal BMD=T score≥−1.0, osteopenia=−2.5<T score<−1.0,
osteoporosis=T score≤−2.5
Table 3 Comparison of early SpA patients with low and normal BMD
Low BMD (N=60) Normal BMD (N=70) p value
Demographic variables
Mena 50 (83.3) 36 (51.4) <0.001
Ageb (years) 38.1 (8.9) 38.0 (9.3) NS
Disease-related variables
Time since diagnosisc (months) 7.7 (3.0–15.0) 5.9 (1.9–14.9) NS
Disease durationc (years) 6.7 (3.8–13.8) 6.1 (2.1–10.3) NS
Ankylosing spondylitisa 49 (81.7) 45 (64.3) 0.027
HLA-B27, positivitya 43 (71.7) 53 (75.7) NS
ESRc (mm/hr) 9.0 (5.0–21.0) 9.0 (4.0–17.5) NS
CRPc (mg/l) 9.0 (2.0–15.0) 3.5 (1.8–7.0) 0.008
BASDAIb (0–10) 4.4 (2.4) 4.1 (2.2) NS
BASFIc (0–10) 3.5 (1.1–6.1) 1.8 (0.7–3.7) 0.004
BASMIc (0–10) 2.0 (1.0–3.0) 1.0 (0.0–2.0) <0.001
Uveitisa 11 (18.3) 20 (28.6) NS
Psoriasisa 5 (8.3) 6 (8.6) NS
Inflammatory bowel diseasea 2 (3.3) 3 (4.3) NS
Peripheral arthritisa 14 (23.3) 29 (41.4) NS
Other BMD-related variables
BMIb (kg/m2) 24.7 (3.6) 25.2 (4.0) NS
Postmenopausal statusa 1 (1.7) 1 (1.4) NS
Previous non-vertebral fracturesa 22 (36.7) 31 (44.3) NS
NS not significant (p≥0.05), ESR erythrocyte sedimentation rate, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity
Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index
a Number (%)
bMean (SD)
cMedian (IQR)
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women, 77% had normal BMD, 21% osteopenia, and 2%
osteoporosis. To summarize, there was a significant difference
between men and women with regard to the development of
low BMD. Male patients turned out to have higher BASMI
scores than female patients (data not shown).
Discussion
This study shows a high prevalence (47%) of low BMD in
both femur and lumbar spine in SpA patients with early
disease. Low BMD proved to be significantly associated
with male gender and the severity of the disease, as shown
by high BASMI and BASFI levels. Our study is the first to
report on BMD status in an early SpA population, which is
in contrast with other studies reporting only on AS.
Furthermore, even in most “early AS studies”, AS patients
usually have longer disease durations [19–21].
Osteoporosis is a well-known complication of long-
standing AS. However, studies about the degree of
osteoporosis in a SpA population and its relation with risk
factors are limited, particularly in patients with an early
disease. Traditional risk factors affecting the BMD state in
the general population are female gender, increasing age,
low body mass index, menopause, and the presence of
chronic inflammatory diseases. No significant differences
were found between SpA patients with low and normal
BMD in terms of these risk factors in this study. In contrast
with the general population, in this study, low BMD values
were particularly found in relatively young men instead of
women who usually have lower BMD values due to lower
peak bone mass and bone loss during menopause, although
the number of postmenopausal women in this study was
very low. The relatively high prevalence of osteoporosis in
male patients could be explained by a higher disease
activity in men compared with women, although this could
not be demonstrated (with the BASDAI) in our cross-
sectional study. Another possibility could be a difference in
hormone levels, testosterone, and estrogen in AS patients
(compared with the healthy population), although observa-
tions in previous studies were not conclusive on this subject
[22–25] and could not explain the early onset of osteopo-
rosis in male patients. However, it is possible that
premenopausal women are less prone to SpA-related bone
loss than male patients due to the protective action of
estrogen.
In SpA (especially AS), other potential risk factors for
bone loss occur, such as inflammation and mechanical
factors: rigidity of the spine resulting in limited mobility
and reduced physical activity due to pain and stiffness. Data
about these risk factors, high disease activity variables
such as ESR, CRP, BASDAI, as well as indicators of low
functional capacity such as high BASFI and BASMI scores,
are not consistently reported in relation with low BMD
levels in different studies [2, 19, 20]. In this study, disease
activity parameters, such as increased CRP and high
BASFI and BASMI scores, correlated significantly with
low bone mass in femoral neck as well as in lumbar spine.
Inflammation in SpA and decreased functional capacity
turned out to be major contributors to this process.
The role of pro-inflammatory cytokines might be
important for the onset of osteoporosis because increased
TNF-alpha levels have been found in patients with AS
compared with subjects with non-inflammatory back pain,
and correlations have been found between disease activity
and markers associated with an increased bone metabolism
[26]. This supports the hypothesis that increased inflam-
matory activity in AS will lead to increased bone resorption
and decreased bone density.
Mechanical factors, such as rigidity of the spine due to
ankylosis, seem to be a less likely explanation for lowBMD in
our group of patients because they were relatively young and
had a short disease duration. The fact that low BMD is
encountered in a young population with an early disease is
very interesting. In most other studies, “early” often refers to
patients who have not yet developed ankylosis or other
radiological progression signs, or these studies made use
of disease durations as time since diagnosis and then referred
to a disease duration of <10 years [19–21]. The issue of
defining disease duration has been much debated in the AS
Table 4 Relation between disease-related variables and low BMD
Univariate Multivariate
Variables Odds ratio (CI) p value Odds ratio (CI) p value
Men 4.72 (2.10–10.78) <0.001 4.18 (1.73–10.09) 0.002
Ankylosing spondylitis 2.48 (1.09–5.60) 0.030 1.54 (0.61–3.86) 0.359
CRP 1.04 (1.01–1.08) 0.018 1.03 (0.99–1.07) 0.198
BASFI (0–10) 1.24 (1.07–1.44) 0.004 1.18 (1.00–1.39) 0.053
BASMI (0–10) 1.72 (1.32–2.25) <0.001 1.54 (1.14–2.07) 0.005
CRP C-reactive protein, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index
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literature, and with the knowledge of today, the onset of the
first symptoms is considered to be most important [27]. The
majority of the early SpA patients included in this study had
a short time since diagnosis (median of 6.6 months) and
disease duration (median of 6.3 years), counting from the
very first symptoms of axial manifestations (i.e., inflamma-
tory back pain or AS specific symptoms), which is shorter
than the mean duration of 8–10 years before diagnosis, as
mentioned in the literature [28–30].
Low BMD in this early SpA group is equally prevalent
in femur and spine, although osteoporosis is slightly more
prevalent in the spine (7.7%) compared with the femur
(2.3%). This observation is in contrast with long-standing
AS in which reduced bone mass is particularly reflected by
low BMD in the hips. The lumbar spine often shows
misleading high BMD values due to bridging syndesmo-
phytes and ankylosis, which might mask osteoporosis in
AS patients with an advanced disease [1, 2, 10, 11].
Although it seems unlikely that many syndesmophytes and
ankylosis of the vertebrae have developed already at such
an early stage of the disease, we checked the radiographs of
the lumbar spine. Only a few patients (nine patients) had a
small syndesmophyte which did not influence the presented
results of the analyses (data not shown).
Finally, a relatively small group (28%) of our early SpA
cohort had diagnoses other than AS, of which 31% turned
out to have a low BMD. In the univariate analysis, the
diagnosis AS seemed to be significantly related to low
BMD, but after correction for other risk factors in the
multivariate model, this association was not found. Therefore,
patients with spondylarthropathies as a group are prone to
have low BMD at an early stage of the disease.
In conclusion, this study demonstrates that half of the
early SpA patients already show low BMD. Especially men
at a relatively young age with high disease severity
(indicated by impaired physical function with high BASMI
and BASFI levels) are prone to have low BMD, and there is
a strong tendency for an association with the diagnosis AS
and high CRP. At early stages of the disease, no differences
are found in low BMD between hips and spine.
These findings are clinically relevant since reduced bone
mass will increase the risk of vertebral deformities and
fractures. Therefore, we would like to emphasize the need
for more alertness for osteoporosis and osteopenia in
spondylarthropathy patients at an early stage of the disease.
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